



Concert Genetics Navigator

Increase consistency and streamline the medical review process for genetic testing

Today, there are more than 175,000 unique genetic testing products on the market, and an average of 10-15 new products are added each day. The number of tests, scope of clinical applications, and associated clinical evidence are all expanding, challenging the ability of health care providers and insurers to keep up. Many tests are still billed using multiple codes in varying combinations, compounding the difficulty of making evidence-based coverage and payment decisions.*

Payers need a way to integrate the extensive collection of Concert Genetics molecular diagnostics criteria into their existing utilization management (UM) workflow to ensure efficiency and accuracy of authorization decisions.

The Concert Genetics Navigator solution provides Concert's evidence-based coverage criteria and comprehensive GTU™ test identification system integrated with the InterQual® Medical Review Service solution, enabling efficient, evidence-based decisions in the fast-growing precision medicine space.

Seamless workflow integration – Concert Genetics content is seamlessly integrated into your existing InterQual workflow for convenient access.

Structured Q&A format – Concert Genetics coverage criteria have been converted into an easy-to-use, interactive Q&A format, helping you navigate through the criteria to reduce review times, support review consistency and streamline the prior authorization process.

Extensive test coverage – More than 18,000 molecular and genetic diagnostic tests, covering about 90% of health plan spend in genetic testing, are mapped to specific criteria with the remainder of the 175,000 available tests covered by general criteria.

Includes GTU test identification codes – The Genetic Testing Unit (GTU) provides a unique identifier for each genetic test, enabling you to quickly identify the correct criteria to apply. This is particularly helpful when the CPT® code(s) for the test align with multiple sets of criteria and it's unclear which to apply.

Semi-annual updates – Criteria reflect the most current, relevant evidence on an extensive set of tests and also cover newly developed diagnostic capabilities.

Categories

- Oncology
- Hereditary cancer
- Carrier screening
- Non-invasive prenatal testing (NIPT)
- Rare and inherited disease
- Exome and genome
- Pharmacogenomic

Also available:

InterQual® Molecular Diagnostics Criteria –

For the review of appropriate diagnostic testing for more than 800 molecular and genetic tests. Review results provide recommended services, including test-sequence recommendations and alternative recommendations based on the clinical scenario. Updated semi-annually.

Medicare Molecular Diagnostics and Lab Navigator –






For the review of diagnostic testing and labs for Medicare/Medicare Advantage patients to help ensure compliance with CMS policies (NCDs and LCDs). Updated every 6 weeks.

* Concert Genetics 2022 Genetic Test Price Transparency Report.

GTU is a trademark of Concert Genetics. CPT is a registered trademark of the American Medical Association (AMA).

Clinical decision support across the continuum of care

InterQual criteria and industry content

 Level of Care	 Behavioral Health	 Ambulatory Care Planning	 Industry Content	 Care Coordination
Acute Adult*	Adult and Geriatric Psychiatry	Procedures*	The ASAM Criteria®	Coordinated Care
Acute Pediatric*	Child and Adolescent Psychiatry	Imaging	Concert Genetics	Patient Education
Long-Term Acute Care*	Substance Use Disorders	Durable Medical Equipment*	Medicare Behavioral Health	
Inpatient Rehabilitation*	Behavioral Health Services	Molecular Diagnostics	Medicare Procedures*	
Subacute and Skilled Nursing*		Specialty Rx Non-Oncology	Medicare Imaging	
Home Care		Specialty Rx Oncology	Medicare Post-Acute and Durable Medical Equipment	
Outpatient Rehab and Chiropractic		Specialty Referral	Medicare Molecular Diagnostics and Lab	
		Retrospective Monitoring	Medicare Pharmacy	

* Decision Reasons add-on available.

Objective, specific and comprehensive clinical content

InterQual criteria are objective and specific, helping guide consistent, defensible decisions that ensure appropriate, quality care. The portfolio of 5 content suites offers comprehensive content that spans the continuum of care for medical and behavioral health.

Rigorous, evidence-based development process

Our highly trained clinical development team performs an unbiased, systematic review and critical appraisal of the evidence using elements of the GRADE approach to help ensure InterQual criteria reflect the best available clinical evidence. No other criteria provide a higher level of accuracy and timeliness than InterQual. Developed with rigor and objectivity, InterQual criteria are updated frequently to remain current with the latest evidence.

Extensive peer review

Our clinical review panel of more than 1,100 independent, multidisciplinary experts provides extensive, multilevel peer review. For situations that do not lend themselves to accepted research methods, larger and more geographically dispersed groups of clinical experts are used to establish best practices that reflect the current standard of care.

InterQual is used by:

4,300+

provider organizations

300+

payer organizations

100%

RACs, MACs, CMS and BFCC-QIOs

The ASAM Criteria is a registered trademark of the American Society of Addiction Medicine.



optum.com

Optum is a registered trademark of Optum, Inc. in the U.S. and other jurisdictions. All other brand or product names are the property of their respective owners. Because we are continuously improving our products and services, Optum reserves the right to change specifications without prior notice. Optum is an equal opportunity employer.

© 2024 Optum, Inc. All rights reserved. WF12876018 02/24